DS Asset Management
VC Fund
Seoul, South Korea
DS Asset Management is a firm that invests in listed companies and venture firms.
- Total investments:
- 103
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries DS Asset Management invests in
Stages DS Asset Management invests in
Countries DS Asset Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.7M–$15M
- Series B
- $5.3M–$29M
- Series C
- $11M–$51M
Investment Focus
Industry
- Biotechnology 19 (18%)
- Medical 12 (12%)
- Information Technology 11 (11%)
- E-Commerce 10 (10%)
- Artificial Intelligence 10 (10%)
Stage
- Series B 28 (27%)
- Series A 26 (25%)
- Series C 21 (20%)
- Venture - Series Unknown 9 (9%)
- Series D 6 (6%)
Country
- South Korea 80 (78%)
- United States 4 (4%)
- Japan 1 (1%)
- Sweden 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hee Joong Kim
Portfolio Manager
|
Portfolio Manager | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DEEPX
|
DEEPX is a Korean AI hardware system solution company. | $29.4M / Series D / Aug 03, 2026 | |
Labrador Labs
|
LABRADOR LABS began as an academic research collaboration initiative to develop an automated analytic method for detecting both known and new vulnerabilities. | $9.7M / Series B / Mar 25, 2026 | |
Olive International
|
Olive International is an operator of lifestyle brands intended to develop and grow a targeting brand. | $3.4M / Series C / Nov 19, 2025 | |
IMBiologics
|
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M / Series C / Oct 14, 2025 | |
Bilix
|
Bilix is a biotechnology company that produces anti-inflammatory and cancer therapy drugs for inflammatory diseases. Bilix, developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. | Series B / Jul 17, 2025 | |
AimedBio
|
AIMEDBIO provides therapeutic solutions to patients with serious brain diseases. | $37.1M / Venture - Series Unknown / Jun 02, 2025 | |
SDT
|
SDT is an IoT platform company that specializes in product design, hardware engineering, and cloud service. | $7.1M / Dec 03, 2024 | |
|
AimedBio
|
AIMEDBIO provides therapeutic solutions to patients with serious brain diseases. | $29.2M / Series B / Jul 31, 2024 | |
RFPT
|
RFPT specializes in the development of RF modules for semiconductor equipment. Their product line includes RF generators, matching units, filters, and related accessories, all designed to enhance the performance and efficiency of plasma-based applications. It delivers solutions that meet the rigorous demands of the semiconductor industry byintegrating advanced RF power semiconductor technologies. | $9.3M / Convertible Note / Nov 20, 2023 | |
Graphene Square
|
Graphene Square is a pioneer in the commercialization of graphene material and graphene films for use as a transparent conductor and in other electronics applications. Established as a spin-off of the research of Prof. Byung Hee Hong at Seoul National University and with headquarters in Seoul, Korea. Graphene Square will continue to stay as theworld leader of the graphene commercialization research, also will continue to provide the best quality graphene and equipment to all over the world for the continuous development of carbon and 2D materials for the bright future of the science and technology for mankind. | $14.7M / Venture - Series Unknown / Nov 16, 2023 | |
| See all 103 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does DS Asset Management invest in?
DS Asset Management invests primarily in Biotechnology, Medical and Information Technology startups, most often at Series B and Series A stage. Most of the 103 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DS Asset Management's check size?
DS Asset Management typically joins rounds of $1.7M–$15M at Series A, $5.3M–$29M at Series B and $11M–$51M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DS Asset Management participates in.
How do I contact DS Asset Management?
Public channels for DS Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DS Asset Management?
The team at DS Asset Management includes Hee Joong Kim (Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
